Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Imugene ( (AU:IMU) ) is now available.
Imugene Limited has announced promising early efficacy results from its Phase 1b trial of azer-cel, an allogeneic CD19 CAR T therapy, in CAR T-naïve patients with various B-cell lymphomas. The trial showed an 83% overall response rate and a 50% complete response rate among the six evaluable patients, with enrolment progressing faster than previous cohorts. This progress highlights the substantial clinical demand and potential for expedited clinical paths, particularly in areas of unmet need.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company specializes in off-the-shelf, allogeneic CAR T therapies, targeting a range of B-cell lymphomas, including rare subtypes where no CAR T products are currently approved.
Average Trading Volume: 2,807,755
Technical Sentiment Signal: Sell
Current Market Cap: A$119.8M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.